Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Leases (2019 - 2025)

Plus Therapeutics has reported Current Leases over the past 7 years, most recently at $56000.0 for Q4 2025.

  • Quarterly Current Leases rose 27.27% to $56000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56000.0 through Dec 2025, up 27.27% year-over-year, with the annual reading at $56000.0 for FY2025, 27.27% up from the prior year.
  • Current Leases was $56000.0 for Q4 2025 at Plus Therapeutics, up from $21000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $127000.0 in Q2 2021 and troughed at $21000.0 in Q3 2025.
  • The 5-year median for Current Leases is $107000.0 (2022), against an average of $90400.0.
  • The largest YoY upside for Current Leases was 27.27% in 2025 against a maximum downside of 69.12% in 2025.
  • A 5-year view of Current Leases shows it stood at $111000.0 in 2021, then decreased by 0.9% to $110000.0 in 2022, then grew by 9.09% to $120000.0 in 2023, then crashed by 63.33% to $44000.0 in 2024, then increased by 27.27% to $56000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Current Leases are $56000.0 (Q4 2025), $21000.0 (Q3 2025), and $30000.0 (Q2 2025).